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Precis: Many breast cancer patients consider contralateral prophylactic mastectomy (CPM), 
and consideration relates to their decision style and values. Understanding these styles and 
values could provide an opportunity for improving patient clinician discussions about breast 
cancer treatment.   
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ABSTRACT  
 
Background: Little is known about how the individual decision styles and values of breast 
cancer patients at the time of treatment decision making are associated with consideration of 
different treatment options, specifically with consideration of contralateral prophylactic 
mastectomy (CPM). 
Methods: We identified newly diagnosed patients with early-stage breast cancer treated in 
2013-14, identified through SEER registries of Los Angeles & Georgia, and surveyed them 
about 7 months after surgery (N=2578, RR=71%). The primary outcome was consideration of 
CPM (strong vs. less strong). We assessed the association between patients’ values and 
decision styles and strong consideration using multivariable logistic regression.  
Results: About one quarter (25%) of women reported strong/very strong consideration of CPM, 
and another 29% considered it moderately/weakly. Decision styles, including “rational-intuitive” 
approach to decision making, varied.  The factors most valued by women at the time of 
treatment decision making were: avoiding worry about recurrence (82%), and reducing the need 
for more surgery (73%). In multivariable analysis, patients who preferred to make their own 
decisions, those who valued avoiding worry about recurrence, and who valued avoiding 
radiation significantly (P<0.05) more often strongly considered CPM, while those reported being 
more “logical” and who valued keeping their breast less often did so. 
Conclusions: Many patients considered CPM, and consideration was associated with both 
decision style and values. The variability in decision style and values observed in this study 
suggests that formally evaluating these characteristics at or prior to the initial treatment 
encounter could provide an opportunity for improving patient clinician discussions.   
 
Keywords:  breast cancer, contralateral prophylactic mastectomy, population-based survey, 
decision-making, decision styles 
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INTRODUCTION 
 
The surge in use of contralateral prophylactic mastectomy (CPM) after diagnosis of 
breast cancer has motivated interest in understanding how the treatment decision-making 
process can drive patient desire for aggressive procedures that increase morbidity in the 
absence of a survival benefit.  CPM has increased from relatively few among women who do 
not have an elevated risk of developing a second primary breast cancer to a rate of over 20% in 
this population and now represents about half of mastectomy performed for breast cancer in the 
United States.1-3 Importantly, many more women consider getting the procedure than actually 
receive it.  
Remarkably little research has been done to examine the psychological factors that drive 
patient desire for CPM.  Several studies that have examined correlates of the use of CPM have 
observed that the procedure is received primarily by more highly educated, Caucasian, and 
insured patients.2-7 Research that has explored the patient perspective has found women’s 
choices for the procedure to be driven by worry about recurrence and desire for “peace of mind” 
as well as the desire for better cosmetic outcomes.2,5  However, this literature has been limited 
by a focus on  the characteristics of patients who ultimately receive CPM.  Indeed, very little is 
known about all patients who think seriously about receiving CPM, including those do not 
ultimately receive it.  Surgeons must be able to identify this much broader group of women 
whose concerns must be addressed as part of the treatment decision making process.  
To address this gap in the literature, our study had two objectives. First, we 
characterized patient perspectives about the importance of different factors related to 
treatments (values) and underlying attitudes toward  decision-making (decision styles) in a 
large, diverse, population-based sample of patients with early-stage breast cancer at average 
risk of development of a second primary cancer.  Second, we evaluated correlates of strong 
consideration of CPM, including patient decision style and values. 
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METHODS 
Study Population 
The iCanCare Study, a large, diverse, population-based survey study of women with 
favorable prognosis breast cancer, accrued women ages 20-79 with newly diagnosed breast 
cancer (DCIS and stages I-II, <5cm in size) as identified by rapid reporting systems from the 
Surveillance Epidemiology and End Results (SEER) registries of Georgia and Los Angeles 
County in 2013-2014. Black, Asian, and Hispanic women were oversampled in Los Angeles.8  
We selected 3,880 of whom 249 women were later deemed ineligible due to having a prior 
cancer diagnosis or stage III or IV disease; residing outside the SEER registry area; being 
deceased, too ill or unable to complete a survey in Spanish or English. Of 3,631 eligible women 
remaining, 1,053 did not return mailed surveys, refused to participate or were lost to follow up. 
Among the 2,578 respondents (71%), 216 were excluded due to having bilateral disease and/or 
being a genetic mutation carrier as reported on the survey. The resulting analytic sample was 
2,362 women (Supplementary Figure 1). 
 
 
Data Collection 
Patients were sent surveys approximately 2 -3 months after surgery, with median 
completion time 6-7 months post surgery.  We provided a $20 cash incentive and used a 
modified Dillman method for patient recruitment.9 All materials were sent in English and Spanish 
to those with Spanish surnames.8 Survey responses were then merged with clinical data from 
SEER. The study was approved by the Institutional Review Boards of the University of 
Michigan, University of Southern California, and Emory University.  
 
Questionnaire Design and Content 
Patient questionnaire content was guided by a conceptual framework, research 
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questions, and hypotheses. We chose established measures when available and developed 
new measures when necessary, drawing from the literature and our prior research.10-12 We used 
standard techniques to assess content validity, including review by survey design experts, 
cognitive pre-testing with patients, and pilot studies in selected clinic populations. 
 
Measures 
Primary Outcome: Consideration of CPM 
We asked women to indicate on a 5-point Likert Scale how much they considered having 
a mastectomy on their unaffected breast (from not at all to very strongly). We looked at any 
consideration (weakly, moderately, strongly, or very strongly) vs not at all, as well as 
categorization into 2 groups: strongly/very strongly vs other groups. For all but our initial 
descriptive analyses of this variable, we focused on the latter dichotomized comparison. 
 
Key Independent Variables  
Decision Style Factors 
We used four measures designed to assess women’s underlying approach to decision-
making (decision-styles) based on prior work.  
Decision Making Apprehension Scale: This scale consisted of 4 items, each on a 5-point 
Likert Scale (not at all to almost always), designed to assess how women normally approach the 
emotional side of decision-making: a) I worry about making a bad decision, b) I struggle to 
decide what the right decision is, c) Once I make a decision, I don’t look back, and d) I worry a 
lot about the outcomes of my decisions. The Cronbach alpha for the scale was 0.78 and it 
formed a single factor with higher scores indicating more decision-making apprehension. 
Decision Making Traits: We asked 5 questions to assess the degree to which women 
indicated they were usually more rational or more intuitive in their approach to general decision-
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making based on literature in decision psychology.13 The items each had a 4-point Likert-like 
scale: 1) did you rely on your instincts and feelings or weigh the pros and cons (1 – instincts to 4 
– pros and cons); 2) Were you more intuitive or more rational in your thinking? (1-more intuitive 
to 4- more rational); 3) Did you really think things through or did you go with your first instinct? 
(1 – went with my first instinct to 4- thought things through); and 4) Did you spend a lot of time 
reviewing the details or did you make decisions quickly? (1- quick decisions to 4-review details), 
and 5) Did you do what seemed most logical or did you just follow your heart? (1- follow heart to 
4-more logical). Each of these items was dichotomized. 
Decision Autonomy Preference: We asked 2 questions to assess desired role in 
decision-making. They were asked to indicate the degree they wanted their doctor to tell them 
what to do, and the degree to which they preferred to make their own breast cancer treatment 
decisions, each on 5-pt scale from not at all to all the time. Each was categorized into (quite a 
bit/all the time) vs less.14 
Patient Values 
We assessed the women’s reports of the importance of sixteen underlying values related 
to breast cancer treatment. For each value, we asked women to indicate how important it was to 
her at the time of making her treatment decision on a 5-point Likert Scale (from not at all to very 
important). For analysis, an indicator was created for reporting “very” or “quite” important vs. 
other categories.  
 
Covariates 
Covariates used in this analysis included patient demographics obtained from the patient 
questionnaire. We included age, race/ethnicity (White, Black, Latina, Asian, Other/Unknown), 
educational attainment (high school graduate or less, some college or more), marital status 
(married/partnered vs. not), income group (<40K, 40-<90K, >90K), insurance status (Private, 
Medicare, Medicaid, other, none), bra cup size (A/B, C, D, DD+) and family history of breast 
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cancer (none vs. 1 or more first degree relatives). We also included whether the patient reported 
having had an MRI (yes/no/missing). Stage (0, I, II) was collected from SEER. An indicator of 
high risk for having a genetic mutation was created from both patient report and SEER 
variables, as described in other work.3  Geographic site (GA or LA) was also included to account 
for regional differences. 
Statistical Analyses 
We first calculated the proportion of women who considered CPM strongly or very 
strongly (hereafter referred to as “strong consideration”) overall, and by all demographic and 
clinical factors, including risk status. We generated descriptive statistics of each decision style 
measure, and for all 16 values overall, by generating the proportion indicating quite/very 
important for each value. We then evaluated associations between these measures and strong 
consideration of CPM after adjusting for the covariates noted above. 
Multivariable logistic regression was used to explore correlates of strong consideration of 
CPM, including decision style factors, values and covariates that remained significant at P<0.05 
in the adjusted analyses.  Parsimonious multivariable models were constructed using backward 
selection techniques using a three step approach.  First decision style factors and values were 
modeled separately each along with all demographic and clinical factors to determine important 
decision style factors and values.  Second, significant decision style and values from each 
model were then modeled simultaneously again retaining all demographic and clinical factors.  
Finally, significant decision style factors, values, demographic and clinical factors were retained 
to arrive at the final parsimonious model. This model was adjusted for clustering at the surgeon 
level to account for potential surgeon-level practice attributes that may impact patients’ 
consideration of CPM, such as the availability of or propensity to refer to reconstructive 
surgeons.15-17  
All statistical analyses incorporated weights to account for differential probabilities of 
sample selection and non-response.  Survey and SEER item non-response was low (<5%) for 
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all covariates. We compared the distributions between non-respondents and respondents for 
age, race, stage and site.  White patients (vs. minorities) and those with stage I cancer (vs. 
stage II) were significantly more likely to respond, which was then addressed by weighting to 
ensure that the analyses were representative of the original population.  
To correct for the potential of bias due to missing data, values for missing items were 
imputed using sequential multiple imputation (SMI).18,19 Five multiply imputed datasets were 
analyzed and model estimates combined to account for additional uncertainty due to imputation. 
Results were compared between SMI analyses and complete-case analyses for any meaningful 
differences.  Odds ratios (OR) with 95% confidence intervals (CI) are reported for models, with 
p-values ≤0.05 considered significant.  All analyses were performed using SAS version 9.4 
(Cary, NC). 
 
Results 
Sample Characteristics 
The characteristics of the sample overall and by degree of consideration of CPM are 
provided in Table 1.  Mean age was 62 (SD 11) years.  Overall, 25% of patients had DCIS, 47% 
Stage I disease, and 25% Stage II disease.  Slightly over half were White (54%); 430 (18%) 
were Black, 413 (14%) Latina, and 205 (9%) Asian.  Most had some college or more 
educational attainment (72%). The majority (1260, 54%) had private insurance, but 682 (29%) 
had Medicaid and 328 (13%) Medicare.  A quarter (24%) reported having a first-degree family 
member with breast cancer.  Most (71%) were not at high risk for a second primary breast 
cancer.  
 
Overall, about one quarter (25%) of women reported strong or very strong consideration 
of CPM, and another 29% considered it moderately or weakly. Of those who considered it 
strongly, 13% received unilateral mastectomy and 16% breast conservation. In bivariate 
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analyses, women who considered CPM strongly/very strongly were younger, more educated, 
white, had private insurance, and had a family history of breast cancer, and more often from 
Georgia. 
 
TABLE 1 
 
 
Decision styles  
The mean score on the decision apprehension scale was 2.5 (range 1-5, from not very 
to very apprehensive). More than half of respondents reported that they were more rational than 
intuitive (75%), more often thought through decisions than went with their instinct (78%), more 
often reviewed details than made quick decisions (61%), and were more logical than following 
their heart (83%) in their approach to treatment decision-making. Over half (59%) indicated they 
wanted their doctor to tell them what to do quite/all the time, and just over one third (37%) 
reported that they preferred to make their own decisions quite a bit/all the time. 
 
Values 
There was considerable variation in the factors valued by patients in making treatment 
decisions. Figure 1 shows the % of patients who indicated each value or value group was “very 
or quite important” to them in making their treatment decision. The most common value women 
reported being quite/very important was allowing them to avoid worry about the cancer coming 
back (82%), followed by reducing the need for more surgery (73%), being the newest, most 
advanced treatment (69%), and avoiding treatment side effects (67%). The least commonly 
reported to be quite/very important was to have the same treatments as other women had 
received (23%). 
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Factors associated with Strong/Very Strong Consideration of CPM 
Table 2 shows the odds ratios for associations between individual decision style and 
values and strong consideration of CPM, after adjustment for the patient demographic and 
disease characteristics in separate regression models. Having higher levels of decision 
apprehension was modestly associated with strong consideration (OR: 1.14; 95% CI 0.99-1.31), 
while women who reported more logical approaches to decision-making were less likely to have 
strong considered CPM (OR: 0.52; 95% CI 0.31-0.71). Women who preferred their doctor make 
the decision less often strongly considered CPM (OR: 0.69; 95% CI 0.55-0.87), while women 
who preferred to make their own treatment decisions more often strongly considered CPM (OR: 
1.74; 95% CI 1.39-2.18).  Several values were significantly associated (P<0.01) with strong 
consideration of CPM, including women who said the following were quite/very important at the 
time of treatment decision making: avoiding worry about the cancer coming back, avoiding 
exposure to radiation, requiring fewer trips back and forth for treatment, and choosing 
treatments that were most extensive. Conversely, women who said that choosing treatments 
that were least extensive, allowed them to keep their natural breast, were the same treatments 
as other women had were significantly (P<0.001) less likely to strongly consider CPM. 
 
Table 2  
 
Figure 2 displays a forest plot showing the multivariable parsimonious logistic regression 
results for strong consideration of CPM, adjusted for clustering at surgeon level. Patients who 
had a family history of breast cancer and a larger breast cup size had higher odds of strong 
consideration of CPM than their counterparts (OR: 2.19; 95% CI 1.65-2.91, OR 1.76; 95% CI 
1.17-2.65, respectively), while those from Georgia had lower odds (OR: 0.60; 95%CI 0.42-0.85). 
Latina women also reported strong consideration of CPM more often than white women (OR: 
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2.14; 95% CI 1.37-3.34), while African American women reported strong consideration of CPM 
less often than white women (OR: 0.63; 95% CI 0.43-0.93).  Two decision styles remained 
significantly associated with strong consideration of CPM in the multivariable model: women 
who preferred to make their own treatment decisions more often strongly considered CPM (OR: 
1.56; 95% CI 1.21-2.01), while women who reported being “more logical” in their decision 
making less often strongly considered CPM than those who reported “following their heart” (OR: 
0.50; 95% CI 0.34-0.72). Three values remained significant: avoiding worry about the cancer 
coming back (OR: 2.26; 95% CI 1.40-3.66), avoiding radiation exposure (OR: 2.85; 95% CI 
2.19-3.68) were both associated with strong consideration, while allowing you to keep your 
natural breast was significantly and inversely associated with strong consideration of CPM (OR: 
0.12; 95% 0.08-0.17) 
 
 
DISCUSSION 
In this large, diverse, population-based sample of newly diagnosed breast cancer 
patients with favorable prognosis, we found considerable variation in both the manner with 
which patients reported approaching treatment decision making (decision styles) as well as in 
what women valued at the time of treatment decision making; while most strongly valued 
avoiding worry about the cancer coming back, other factors were also important to many 
women. We further found that nearly a quarter of women strongly or very strongly considered 
having their unaffected breasts removed as part of treatment for their breast cancer, and 
another 29% considered it moderately or weakly. Our study contributes to the literature about 
the rise in CPM by deconstructing the decision-making process.  Prior to receipt of CPM, all 
patients must move through a process of weighting the treatment options and consider how the 
procedure aligns with their values. Factors associated with consideration, particularly strong 
consideration, are potentially actionable targets for education and intervention. 
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Importantly, our results suggest that “values” matter slightly more than underlying 
personality traits in determining who strongly considers this procedure, though some decision 
styles were relevant. Our measure of decisional apprehension—developed to assess the type of 
person who may be more likely to make a decision for extensive treatment to avoid regretting it 
later—was notably not significantly associated with strong consideration when other factors 
were included in our model.  Similarly, while most of the “rational-intuitive” items were not 
associated with strong consideration, women who endorsed being more logical in their decision-
making less often strongly considered this procedure. This held even when controlling for 
educational status, further underscoring the importance of this finding across all types of 
patients. This finding further suggests that having a better understanding a woman’s underlying 
approach—logical vs. more emotional (i.e., “going with the gut”)—may provide opportunities for 
individualizing the approach to education about risks and benefits.  
We also found that women who reported desiring to play a more active role in decision-
making more often strongly considered CPM. This finding is consistent with prior work showing 
that more involved patients, those who report making patient-driven decisions rather than 
shared or surgeon-driven decisions, more often chose mastectomy, at a time when CPM was 
not a widely performed procedure. 10,11 Our current result confirms that such patient-led 
decision-making is also associated with consideration of even more extensive surgery than 
unilateral mastectomy. These findings call into question the notion that simply involving patients 
in decision making is likely to translate to less overtreatment20. They further suggest that 
perhaps we need to refocus efforts on targeting patients who desire considerable control in the 
decision making process, as well as on aspects of decision-making that are not purely rational. 
The importance of affect in general decision-making has been identified,21,22 and highlighted in 
the seminal work by Kahneman.23 Our findings support that educational efforts in breast cancer 
treatment should address the intuitive or affective reaction patients have to the meaning of the 
diagnosis and the prospects of the arduous treatment course, as well as the cognitive, aspects 
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of decision-making.  For instance, recognizing that it is not uncommon for patients to have 
activated intuitive/affective rather than rational pathways of decision-making, a common 
psychological shortcut or heuristic.23,24 This may require interventions using methods targeted to 
this end such as providing patient stories, as well as numerical information, to appeal to the 
emotional nature of this decision.  
Several of the values measured in our study were associated with strong consideration 
in the anticipated direction when adjusting for patient and disease characteristics. When women 
valued things that would align with receiving more treatment, such as avoiding worry about 
recurrence, and choosing treatments that were more extensive, they more often strongly 
considered CPM. Conversely we also found that when women valued things that would align 
with less surgery, such as keeping their natural breast or choosing treatments that were less 
extensive, they less often strongly considered CPM.  
The importance of these values, which have been identified in prior studies,  reinforces 
the need to address directly patients perceptions of risk of recurrence and their reactions to it,25 
as many patients overestimate their actual risk of recurrence following treatment.   Furthermore, 
prior work by our team has shown an asssocaiton between worry about recurrence and 
subsequent receipt of CPM.4 This is particularly concerning given that CPM does not confer 
benefit for recucing recurrence risk or on long term survival in the population studied in this 
analysis (non BRAC1/2 positive, no strong family history of breast or ovarian cancer).26-28 Our 
current finding, that worry is associated with consideration as well as utilization, suggests 
interventions at the time women are considering their treatment options may be useful. 
Furthermore, the powerful desire for many patients to avoid radiation motivates the need to 
ensure they are well educated about the benefits and risks of treatment options that include this 
modality as an adjuvant. 
Aspects of this study merit comment. Strengths of this study include a large, diverse 
sample, high participation rate, and use of unique patient reported measures. However, the 
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study has some limitations. Patients lived in two geographic regions, so may not represent all 
U.S. breast cancer patients. . We did not have details on some practice factors that might have 
influenced patients desire for CPM such as information and availability of breast reconstruction 
options.  However, we did control for clustering by surgeon and geographic locations. Finally, 
associations observed in the study are not necessarily causal.   
 
IMPLICATIONS 
Our results have important implications for patient-clinician communication to support 
individualized treatment decision-making. Many more patients consider having CPM, even in 
the absence of potential for survival benefit, than actually receive it.  Assessing decision style 
and values of patients at or prior to the initial treatment encounter could provide an opportunity 
for improving deliberation by tailoring discussion about treatment options to embrace the 
patient’s own style and values.  There is a need to better educate patients about misperceptions 
associated with their values; for instance ensuring they understand the actual risk of recurrence 
since that value is associated with consideration of more extensive treatment. Our results 
suggest these are key areas for intervention, even in the context of quality improvement or other 
initiatives to ensure appropriate use of treatments. These assessments can further help 
physicians to tailor communications to better target patients who may not wish to defer to 
physicians and/or those who are engaged in more intuitive than rational decision processes. 
 
REFERENCES 
1. Nash R, Goodman M, Lin CC, et al. State Variation in the Receipt of a Contralateral 
Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive 
Unilateral Early-Stage Breast Cancer in the United States, 2004-2012. JAMA Surg. 
2017. 
Page 16 of 39Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
17
2. Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions 
in a population-based sample of patients with early-stage breast cancer. JAMA Surg. 
2017;152(3):274-282. 
3. Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among 
patients with newly diagnosed breast cancer. JAMA. 2017;317(5):531-534. 
4. Hawley ST, Jagsi R, Morrow M, et al. Social and Clinical Determinants of Contralateral 
Prophylactic Mastectomy. JAMA Surg. 2014;149(6):582-589. 
5. Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction 
with contralateral prophylactic mastectomy among young women with breast cancer: a 
cross-sectional survey. Ann Intern Med. 2013;159(6):373-381. 
6. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of 
contralateral prophylactic mastectomy for breast cancer patients: a trend toward more 
aggressive surgical treatment. J Clin Oncol. 2007;25(33):5203-5209. 
7. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic 
mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 
2009;27(9):1362-1367. 
8. Hamilton AS, Hofer TP, Hawley ST, et al. Latinas and breast cancer outcomes: 
population-based sampling, ethnic identity, and acculturation assessment. Cancer 
Epidemiol Biomarkers Prev. 2009;18(7):2022-2029. 
9. Dillman D, Smyth J, Christian L. Internet, Mail, and Mixed-Mode Surveys: The Tailored 
Design Method (3rd ed). Hoboken, NY: John Wiley & Sons; 2009. 
10. Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions 
for breast cancer. J Clin Oncol. 2005;23(24):5526-5533. 
11. Hawley ST, Griggs JJ, Hamilton AS, et al. Decision involvement and receipt of 
mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer 
Inst. 2009;101(19):1337-1347. 
Page 17 of 39 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
18
2. Shumway D, Griffith KA, Jagsi R, Gabram SG, Williams GC, Resnicow K. Psychometric 
properties of a brief measure of autonomy support in breast cancer patients. BMC Med 
Inform Decis Mak. 2015;15(1):51. 
3. Evans JS, Stanovich KE. Dual-Process Theories of Higher Cognition: Advancing the 
Debate. Perspect Psychol Sci. 2013;8(3):223-241. 
4. Martinez KA, Resnicow K, Williams GC, et al. Does physician communication style 
impact patient report of decision quality for breast cancer treatment? Patient Educ  
Couns. 2016;99(12):1947-1954. 
5. Greenberg CC, Lipsitz SR, Hughes ME, et al. Institutional variation in the surgical 
treatment of breast cancer: a study of the NCCN. Ann Surg. 2011;254(2):339-345. 
6. Hawley ST, Hofer TP, Janz NK, et al. Correlates of between-surgeon variation in breast 
cancer treatments. Med Care. 2006;44(7):609-616. 
7. Katz SJ, Hawley ST, Abrahamse P, et al. Does it matter where you go for breast 
surgery?: attending surgeon's influence on variation in receipt of mastectomy for breast 
cancer. Med Care. 2010;48(10):892-899. 
8. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A Multivariate 
Technique for Multiply Imputing Missing Values Using a Sequence of Regression 
Models. Survey Methodol. 2001;27(1):85-96. 
9. Rubin DB. Multiple Imputation for Nonresponse in Surveys. Hoboken, NY: John Wiley & 
Sons; 1987. 
0. Katz SJ, Hawley S. The value of sharing treatment decision making with patients: 
expecting too much? JAMA. 2013;310(15):1559-1560. 
1. Janssen E, van Osch L, Lechner L, Candel M, de Vries H. Thinking versus feeling: 
differentiating between cognitive and affective components of perceived cancer risk. 
Psychol Health. 2012;27(7):767-783. 
Page 18 of 39Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
19
2. Schwarz N. Emotion, cognition, and decision making. Cognition and Emotion. 
2000;14(4):433-440. 
3. Kahneman D. Thinking, Fast and Slow New York, New York: Farrar, Straus, and Giroux; 
2011. 
4. Lerner JS, Li Y, Valdesolo P, Kassam KS. Emotion and decision making. Ann Rev 
Psychol. 2015;66:799-823. 
5. Hawley ST, Janz NK, Griffith KA, et al. Recurrence risk perception and quality of life 
following treatment of breast cancer. Breast Cancer Res Treat. 2017;161(3):557-565. 
6. Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of 
Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival 
for Invasive Breast Cancer. Ann Surg. 2017;265(3):581-589. 
7. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of 
breast cancer. Cochrane Database Syst Rev. 2010(11):Cd002748. 
8. Nichols HB, Berrington de Gonzalez A, Lacey JV, Jr., Rosenberg PS, Anderson WF. 
Declining incidence of contralateral breast cancer in the United States from 1975 to 
2006. J Clin Oncol. 2011;29(12):1564-1569. 
 
Page 19 of 39 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 20
Figure Legends: 
Figure 1: Patient values in breast cancer treatment decision making 
 
Figure 2: Adjusted Associations (Odd Ratios) from Multivariate Model Explaining Patients' 
Strong Consideration of CPM adjusted for clustering at the surgeon level 
 
Supplementary Figure 1: Study Flow Diagram 
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Table 1 Patient Demographic and Clinical Characteristics (n=2362)  
Characteristic Total (N)  
Weighted % or 
Weighted Mean (SD)  
% Strongly 
Considered 
Age at Time of Survey (years)    
Mean age 2,632 61.8 (10.9) 56.4 (11.0) 
    
Study Site    
Georgia 1244 53.9 28.3 
Los Angeles County 1118 46.1 19.2 
 
   
Race/Ethnicity    
White 1273 57.2 25.7 
Black 422 18.0 19.4 
Hispanic 402 13.6 26.8 
Asian 204 8.7 19.3 
Other/Unknown/Missing 61 2.5 22.4 
     
Education     
At least some college  1658 71.9 26.3 
High school graduate or less 679 27.1 17.7 
Missing 25 1.0 33.4 
    
Marital Status    
Married/partnered 1474 62.7 26.1 
Not married 859 36.0 20.7 
Missing 29 1.3 22.5 
    
Income (annual)    
Less than $40,000 719 29.3 21.5 
$40,000 - <$90,000 649 28.3 25.8 
$90,000 or more 579 25.8 28.9 
Missing 415 16.6 18.2 
    
Insurance    
Private 1239 53.6 30.3 
Other public 30 1.2 25.2 
Medicare 672 28.7 14.3 
Medicaid 319 12.6 20.7 
None 11 0.5 28.0 
Missing 91 3.5 20.6 
    
Page 21 of 39 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 22
Table 1 Patient Demographic and Clinical Characteristics (n=2362)  
Characteristic Total (N)  
Weighted % or 
Weighted Mean (SD)  
% Strongly 
Considered 
Cancer Stage    
0 - DCIS 425 25.2 23.1 
I 1238 46.8 22.9 
II 598 24.6 26.8 
Missing 101 3.4 27.5 
    
High Risk (for 2nd primary cancer)    
Yes 636 27.3 33.8 
No 1668 70.7 20.5 
Not known 58 1.9 18.2 
    
Family history breast cancer    
Yes 536 23.4 30.1 
No 1650 69.2 21.9 
Missing 176 7.4 25.6 
    
Breast Cup Size    
A/B 750 31.9 22.8 
C 730 31.0 21.7 
D  473 19.7 24.0 
DD and greater 339 14.5 31.4 
Missing  70 3.0 27.2 
    
MRI    
Yes 1391 59.1 26.7 
No 765 32.9 20.2 
Missing 206 8.1 20.9 
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Table 2. Association of decision style and values variables individually with strong 
consideration of CPM adjusting for covariates* 
 
 OR (95% CI) P value 
Decision Styles   
Decision apprehension scale 1.14 (0.99-1.31) 0.080. 
Rational vs. intuitive 1.18 (0.89-1.57) 0.24 
Think through vs. first instinct 0.91 (0.68-1.21) 0.48 
Review in detail vs. quick decisions 1.09 (0.86-1.37) 0.52 
Logical vs. follow your heart 0.52 (0.37-0.71) <0.001 
Prefer to make own decisions (all/most of time vs. less) 1.74 (1.39-2.18) <0.001 
   
Values   
Avoid worry about cancer coming back 2.27 (1.54-3.35) <0.001 
Reduce the need for more surgery 0.92 (0.71-1.20) 0.54 
Avoid side effects of treatment 1.23 (0.96-1.58) 0.10 
Avoid exposure to radiation 2.59 (2.03-3.30) <0.001 
Require fewer trips back and forth for treatment 1.51 (1.18-1.92) <0.01 
Did not make you feel bad about your body 1.25 (0.99-1.57) 0.05 
Were most extensive possible 1.45 (1.10-1.92) <0.01 
Were least extensive possible 0.70 (0.55-0.91) <0.01 
Allowed you to keep natural breast 0.15 (0.12-0.21) <0.001 
Were the same treatments other women received 0.63 (0.46-0.86) <0.01 
Were the newest most advanced treatments 0.82 (0.64-1.06) 0.13 
Had the shortest recovery time 0.77 (0.61-0.97) 0.02 
Did not require you to spend a lot of your own money 0.85 (0.67-1.09) 0.20 
* adjusted for all covariates included in table 1 
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Figure 1: Patient values in breast cancer treatment decision making  
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Figure 2: Adjusted Associations (Odd Ratios) from Multivariate Model Explaining Patients' Strong 
Consideration of CPM adjusted for clustering at the surgeon level  
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Supplementary Figure: Study Flow Diagram  
 
171x128mm (300 x 300 DPI)  
Page 26 of 39Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
Section B:  Diagnosis and Testing of Your Cancer 
 
Genetic Testing for Cancer Risk 
Genetic testing for cancer risk – often called BRCA tests or multi-gene panel tests – looks for gene mutations or 
changes to see if women and their families have a greater risk of developing breast cancer in the future. 
 
B15. Genetic tests for breast cancer risk are ordered by a doctor or genetic counselor and can be done with 
either a blood test or a saliva test where you rinse your mouth with mouthwash and spit into a tube.   
Have you ever had a blood or saliva genetic test for breast cancer risk that was ordered by a doctor or 
genetic counselor? 
   
Yes No Don’t know 
 
 
 
 
 
 
 
 
 
 
 
 
B16. Why did you get a genetic test?  Please mark ALL that apply. 
 
     My doctor thought I should 
 
     Because of my family history 
 
     My family wanted me to be tested 
 
     To help me decide about my treatment 
     I wanted to get more information about my own health 
 
     Other (please explain): _ _ _ _ _ _ _ _  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
     I wanted to get more information for my family members 
 
 
 
 
 
B15a. Why haven’t you had a genetic test for breast cancer risk?                        
Please mark ALL that apply. 
I plan to have a genetic test in the future 
I don’t know if I’ve had a genetic test 
My doctor didn’t recommend it 
I didn’t want it 
My family didn’t want me to get it 
It was too expensive 
I was afraid I would lose my insurance or have to pay more for insurance 
I was afraid of discrimination 
Other (please explain): _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Please go to B22 “Tumor Tests” on page 7 
Please continue to B17 at the top of the next page 
If you have NOT had a genetic test for breast cancer risk, please skip this page and go to B22 
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B17. When did you have the genetic test? 
   
Before I was diagnosed     
with breast cancer 
After I was diagnosed   
but before I had surgery 
After I had surgery                
to treat my breast cancer 
 
B18. What was the result of the genetic test?  Please mark ONE. 
            I did not have any mutations in the gene tests 
 
            I had a mutation in the BRCA1 or BRCA2 gene that increases the risk of breast cancer 
 
         I had a mutation in another gene (not BRCA1 or BRCA2) that increases the risk of breast cancer 
 
            A gene change was found, but not one that has been shown to increase the risk of breast cancer  
           (sometimes called a “variant of uncertain significance”) 
 
            I don’t know the results 
 
            Other (please explain): _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
B21.  Did the genetic test results influence your decision about whether or not to have both breasts removed? 
      
I was never   
interested in having 
both breasts removed 
Made me 
much less 
interested  
Made me 
less  
interested  
Did not influence 
my decision 
Made me   
more  
interested 
Made me       
much more 
interested  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 28 of 39Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
2 
 
 
Section C:  Your Treatments 
 
Surgery 
C2.  What was the first surgery that you had to remove your breast cancer after the biopsy test? 
 
I did not have any surgery after the biopsy  
 
I had a mastectomy (removal of the entire breast)            
 
 
I had a lumpectomy (removal of the cancer and some surrounding tissue)     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C3.  What kind of mastectomy did you have?   
 I did not have a mastectomy 
 
Mastectomy only – no reconstruction 
 Mastectomy with reconstruction and I kept my own nipple, called a nipple sparing 
or nipple saving mastectomy 
  
Mastectomy with reconstruction and my original nipple was removed 
 
 
a. Did you have a second lumpectomy to remove more breast tissue from the same breast? 
       Yes – I had another lumpectomy to remove more breast tissue from the same breast 
       
No – I only had one lumpectomy 
 
b. Did you have a mastectomy later, on the same breast? 
Yes – I had a mastectomy after my lumpectomy 
 
No – I did not have a mastectomy 
             
c. How strongly did your doctor recommend that you have a mastectomy after your initial 
lumpectomy?  
     
 
Very strongly Strongly Moderately Weakly Not at all 
 
d. How strongly did you request to have a mastectomy after your initial lumpectomy?  
     
 
Very strongly Strongly Moderately Weakly Not at all 
     
 
 
Please go to C3 at the top of 
the next page 
Please continue to C3 on the next page 
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C4.  What type of breast reconstruction did you have? 
 
  I have not had any breast reconstruction surgery 
 
A DIEP flap, TRAM flap, or latissimus dorsi flap (uses your own tissue from the abdomen or back) 
 
An implant (silicone or saline) 
 
Other (please explain):  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
 
 
C5. Did you have a mastectomy on both breasts?  
  
Yes No 
 
 
 
 
  
           
 
C6. How important were the following factors in your decision to have a mastectomy on both breasts? 
 
Not at all 
important 
A little 
important 
Somewhat 
important 
Quite 
important 
Very 
important 
a. My age 
     
 
b. Having a family history of breast cancer 
     
 
c. Wanting both breasts to match after 
reconstruction  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please go to C7 at the 
top of the next page 
Go to C6 
below 
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Section D:  Decision Making 
D1. In general, please tell us how often you have these thoughts and feelings when you make decisions. 
 Never Rarely Sometimes Often Always 
a. I worry about making a bad decision 
     
b. I struggle to decide what the right decision is 
     
c. I get angry at myself when I have made a bad 
decision 
     
d. I worry a lot about the outcomes of my decisions 
     
 
D2.  When making decisions about how to treat my breast cancer… 
 Not     
at all  A little Somewhat 
Quite    
a bit A lot 
a. I weighed the pros and cons of all the treatment options 
     
b. I feel like I really thought through all the issues 
important to the treatment decisions 
    
 
c. I talked with others – family or friends – before making 
treatment decisions 
    
 
d. I talked with other breast cancer patients before making 
treatment decisions 
    
 
e. I spent time thinking about all of the treatment options 
    
 
 
 
D3.  When making decisions about how to treat my breast cancer… 
 Not at 
all 
A little 
bit Somewhat 
Quite  
a bit 
Very 
much 
a. I would like to have had more information 
     
b. I would like to have participated more 
     
c. I am satisfied with the amount of time I had 
     
d. I am satisfied with the amount of involvement I had 
from family and friends  
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D4. When decisions were being made about your treatments, how important was it to you 
that your treatments…   
 
Not at all 
important 
A little 
important 
Somewhat 
important 
Quite 
important 
Very 
important 
a. Reduced the need for more surgery 
     
b. Allowed you to avoid side effects of treatment 
     
c.  Allowed you to avoid exposure to radiation 
     
d. Required fewer trips back and forth for 
treatment visits 
     
e. Did not make you feel bad about your body 
     
f. Kept you from worrying about the cancer 
coming back 
     
g. Allowed you to feel feminine 
     
h. Were the most extensive possible 
     
i. Were the least extensive possible 
     
j. Allowed you to keep your original breast 
     
k. Were what your partner/family wanted you to do 
    
l. Were what your doctor wanted you to do  
     
m. Were the same treatments that other women 
you know have received 
     
n. Were the newest, most advanced treatments 
available  
     
o. Had the shortest recovery time 
     
p. Gave you peace of mind 
     
q. Allowed you to avoid having follow-up 
mammograms 
     
r. Did not require you to spend a lot of your own 
money 
     
s. Had a lower possibility of complications 
     
t. Allowed you to continue to care for your home 
and family 
     
u. Allowed you to continue to work for pay  
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D5. At the time that decisions were being made about your treatments, how much do you feel that                
your preferences were considered?  
   
  
 
Not at all Slightly Moderately Very much Completely 
 
Surgery decisions 
D6.  When did you make a decision about your initial surgical treatment? 
   Before my first visit with a surgeon 
   After my first visit with a surgeon 
   After two or more visits 
 
D7.  Did you see a second surgeon for an opinion about your surgery treatment options? 
    Yes      
 
 
   No             
   
 
D8.  How strongly did the surgeons you consulted for breast cancer recommend one option over the other for 
your initial surgery?  
     
 
Strongly 
recommended 
lumpectomy 
Weakly 
recommended 
lumpectomy 
Did not recommend 
one surgery option 
over the other 
Weakly 
recommended 
mastectomy 
Strongly 
recommended 
mastectomy 
 
 
D9. How strongly did you consider having a mastectomy on both breasts?  
     
 
Very strongly Strongly Moderately Weakly Not at all 
 
 
D10. When you discussed treatment options with your surgeon, was the idea of having a mastectomy on both 
breasts ever discussed?    Please mark ONE. 
 
     No, it was never discussed 
 
     Yes, and I was the first to bring it up 
 
     Yes, and my surgeon was the first to bring it up 
 
     Yes, and another person I brought to my clinic visit was the first to bring it up 
a. Did that second surgeon perform your breast surgery? 
   Yes              No            
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D11. How much time did you spend talking with the surgeons you consulted for breast cancer about having      
a mastectomy on both breasts? 
     
 
No time       
at all 
A little bit          
of time 
Some    
time 
Quite a lot          
of time 
All of the time                                      
(it was the only option we talked about) 
 
 
D12. How strongly did the surgeons you consulted for breast cancer recommend having a mastectomy on both 
breasts? 
     
 
Strongly 
recommended it 
Weakly 
recommended it 
Did not make a 
recommendation – 
left it up to me 
Weakly 
recommended 
against it 
Strongly 
recommended 
against it 
 
 
D13.  How much did the surgeons you consulted for breast cancer oppose your interest in having a  
mastectomy on both breasts? 
      
Not at all A little bit Somewhat Quite a bit Very much I did not have any interest in having a 
mastectomy on both breasts 
 
 
 
D14. My surgeons told me that having a mastectomy on my “other” breast – the breast without cancer – 
would: 
 
 Yes No Not discussed 
a. Give me a better chance of surviving the breast 
cancer I already have 
  
 
b. Reduce the chances of the breast cancer I 
already have coming back 
  
 
c. Reduce the chances of developing a new 
cancer in my “other” breast   
 
d. Improve the cosmetic outcome of my surgery   
 
e. Make my recovery from the surgery take longer   
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Section J – Family History of Cancer 
To help us better understand your family history, please answer the following question to tell us if any of your 
blood relatives have had breast cancer and how old they were at the time of their breast cancer diagnosis. 
J1.  Has your mother ever been diagnosed with breast cancer? 
             Yes, my mother was diagnosed with breast cancer before age 50 
  
             Yes, my mother was diagnosed with breast cancer at or after age 50 
   
             No 
 
             Don’t know 
 
Sisters      
J2. How many sisters do you have? 
       
     0 
       
     1 
       
     2 
       
     3 
       
     4 or more 
J3. How many of your sisters have been diagnosed 
with breast cancer? 
     0      1      2      3 
       
     
     4 or more 
J4. Have any of your sisters been diagnosed with 
breast cancer before age 50? 
 
      Yes             
 
      No             
 
      Don’t know           
Daughters      
J5. How many daughters do you have? 
       
     0 
       
     1 
       
     2 
       
     3 
       
     4 or more 
J6. How many of your daughters have been 
diagnosed with breast cancer? 
     0      1      2      3 
       
      
     4 or more 
J7. Have any of your daughters been diagnosed with 
breast cancer before age 50? 
 
      Yes             
 
      No             
 
      Don’t know           
 
 
J8.  Although it is uncommon, men can also get breast cancer.  Has a man in your family (blood relative) ever 
been diagnosed with breast cancer? 
   
Yes No Don’t know 
 
 
J9.  Have any of your parents, brothers, sisters, or biological (blood related) children ever been diagnosed with  
       any of the cancers below?  Please mark ALL that apply. 
     Ovarian                
cancer 
Uterine                
cancer 
  Prostate                
cancer 
     Colon cancer      Stomach (gastric)                
cancer 
     Pancreatic                
cancer 
Brain                
cancer 
     Sarcoma   
(muscle or bone)                 
     Ocular   
melanoma (eye)                 
     Cutaneous 
melanoma (skin)                 
     Leukemia 
(blood)                 
     None of these                 
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Section K:  Home and Work 
K5.  At the time of your breast cancer diagnosis, what was the total yearly income of your entire 
household, before taxes, from all sources – including child support, alimony, disability, social security, and 
unemployment?   
 
     Less than $5,000 
 
     $40,000-$59,999 
 
     $5,000-$9,999 
 
     $60,000-$89,999 
 
     $10,000-$19,999 
 
     $90,000 or more 
 
     $20,000-$29,999 
 
     Don’t know 
 
     $30,000-$39,999 
 
 
Current Status 
 
K21. Which of the following best describes your current employment status? Please mark ALL that apply. 
 
     Employed full-time 
 
     Retired 
 
     Employed part-time 
 
     Student 
 
     Unemployed and looking for work 
 
     Homemaker 
 
     Temporarily laid off or on sick or other leave 
 
     Other (please explain): _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
     Disabled 
 
K22. Please tell us about your medical insurance right before you were diagnosed with breast cancer as well as 
your medical insurance at the present time.  Please mark ALL that apply in both columns. 
What type of medical insurance…        
 
Did you have right 
before your breast 
cancer diagnosis? Do you currently have? 
a. None 
  
b. Insurance provided through my current or former 
employer or union (including HMO) 
  
c. Insurance provided to another family member (e.g., 
spouse) through their current or former employer or 
union (including HMO) 
  
d. Insurance purchased directly from an insurance 
company (by you or another family member) 
  
e. Insurance purchased from an exchange (sometimes 
called “Obamacare” or the Affordable Care Act) 
  
f. Medicaid or other state provided insurance   
Page 36 of 39Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
10 
 
 
g. Medicare/government insurance   
h. Veterans Affairs (VA, including those who have ever 
used or enrolled for VA health care) 
  
i. Other (please explain): _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  
 
Section M:  A Few More Questions 
 
M1.  Today’s date is:    
 
 
 
M2. About how tall are you?   
 
 
 
M3. At the time of your breast cancer diagnosis, about how much did you weigh? 
 
 
 
 
M4. Before your breast surgery, what was your bra cup size? 
 
     A 
 
     D 
 
     B 
 
     DD 
 
     C 
 
     Other (please explain): _ _ _ _ _ _ _ _ _ _ 
 
M5. In the 12 months before your diagnosis with breast cancer, what was your experience with your 
menstrual periods? 
 
     I had no menstrual periods in the 12 months before my breast cancer diagnosis 
 
     I had regular (or the usual timing of) menstrual periods in the 12 months before my breast cancer 
diagnosis 
 
     I had a change in the timing of menstrual periods in the 12 months before my breast cancer diagnosis 
 
 
M6. In the 12 months before your breast cancer diagnosis, did you experience hot flashes or night sweats 
at any time – even once? 
  
Yes No 
 
_____feet  _____inches     or     _____meters 
 
_______pounds     or     _______kilograms 
 
 
______ / _______ / ________ 
month        day           year 
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M7. What is your birth date?     
 
 
 
M8. When you were diagnosed with breast cancer, what was your marital status? 
 
     Married 
 
     Living with partner 
 
     Divorced 
 
     Widowed 
 
     Separated 
 
     Never married 
 
 
M9.  What is the highest level of education you have completed? 
 
     No high school 
 
     Some college or technical school 
 
     Some high school 
 
     College graduate (Bachelor’s degree) 
 
     High school graduate or G.E.D. 
 
     Graduate degree or higher 
 
M10.  Are you of Hispanic, Latino, or Spanish origin? 
 
     Yes, Mexican, Mexican-American, or Chicano 
 
     Yes, Puerto Rican 
 
     Yes, Cuban 
 
     Yes, another Hispanic, Latino, or Spanish origin (please explain):  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
     No 
 
 
 
M11.  Are you of Jewish descent?    
   
Yes No Don’t know 
 
 
 
 
M12.  For how many years have you lived in the United States?      
 
 
 
 
 
M13.  In what country were you born?  
               Don’t know 
 
______ years 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
_______ / ________ / ____________ 
 month          day                year 
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M14.  In what country was your mother born?                 
               Don’t know 
 
 
 
M15. In what country was your father born?  
               Don’t know 
 
 
 
 
 
 
M16.  Which of the following best describes your race?  Please mark ALL that apply. 
 
     White 
 
     Chinese 
 
     Black or African-American  
 
     Filipino 
 
     American Indian or Alaska Native  
 
     Japanese 
 
     Native Hawaiian or other Pacific Islander  
 
     Korean 
 
     Asian Indian 
 
     Vietnamese 
 
     Other Asian (please explain):  _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
     Other Race (please explain): _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ 
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